Department of Statistics, The Islamia University, Bahawalpur, Pakistan.
Department of Mathematics, School of Arts and Science, University of The Gambia, Serekunda, The Gambia.
Ann Med. 2023 Dec;55(1):285-291. doi: 10.1080/07853890.2022.2160491.
The exhaustive information about non-communicable diseases associated with COVID-19 and severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) are getting easier to find in the literature. However, there is a lack of knowledge regarding tuberculosis (TB) and chronic obstructed pulmonary disease (COPD), with numerous infections in COVID-19 patients.
Priority is placed on determining the patient's prognosis based on the presence or absence of TB and COPD. Additionally, a comparison is made between the risk of death and the likelihood of recovery in terms of time in COVID-19 patients who have either COPD or TB.
At the DHQ Hospital in Muzaffargarh, Punjab, Pakistan, 498 COVID-19 patients with TB and COPD were studied retrospectively. The duration of study started in February 2022 and concluded in August 2022. The Kaplan-Meier curves described time-to-death and time-to-recovery stratified by TB and COPD status. The Wilcoxon test compared the survival rates of people with TB and COPD in two matched paired groups and their status differences with their standard of living.
The risk of death in COVID-19 patients with TB was 1.476 times higher than in those without (95% CI: 0.949-2.295). The recovery risk in COVID-19 patients with TB was 0.677 times lower than in those without (95% CI: 0.436-1.054). Similarly, patients with TB had a significantly shorter time to death (=.001) and longer time to recovery (=.001).
According to the findings, the most significant contributor to an increased risk of morbidity and mortality in TB and COPD patients was the COVID-19.KEY MESSAGESSARS-Cov-19 is a new challenge for the universe in terms of prevention and treatment for people with tuberculosis and chronic obstructive pulmonary disease, among other diseases.Propensity score matching to control for potential biases.Compared to hospitalized patients with and without (TB and COPD) had an equivalently higher mortality rate.
与 COVID-19 和严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）相关的非传染性疾病的详尽信息在文献中越来越容易找到。然而，关于结核病（TB）和慢性阻塞性肺疾病（COPD）的知识却很缺乏，COVID-19 患者中有大量感染。
重点是根据是否存在 TB 和 COPD 来确定患者的预后。此外，还比较了 COPD 或 TB 患者的 COVID-19 患者的死亡风险和康复时间。
在巴基斯坦旁遮普省木尔坦的 DHQ 医院，回顾性研究了 498 例 COVID-19 合并 TB 和 COPD 的患者。研究开始于 2022 年 2 月，结束于 2022 年 8 月。Kaplan-Meier 曲线描述了按 TB 和 COPD 状态分层的死亡时间和康复时间。Wilcoxon 检验比较了两组配对患者的 TB 和 COPD 生存率及其与生活水平的差异。
TB 合并 COVID-19 患者的死亡风险是无 TB 合并 COVID-19 患者的 1.476 倍（95%CI：0.949-2.295）。TB 合并 COVID-19 患者的康复风险比无 TB 合并 COVID-19 患者低 0.677 倍（95%CI：0.436-1.054）。同样，TB 患者的死亡时间明显更短（=0.001），康复时间更长（=0.001）。
根据研究结果，TB 和 COPD 患者发病率和死亡率增加的最重要原因是 COVID-19。
关键信息
SARS-CoV-2 是一个新的挑战，需要在预防和治疗方面进行调整，以应对包括结核病和慢性阻塞性肺疾病在内的其他疾病。
倾向评分匹配以控制潜在偏差。
与未患有（TB 和 COPD）的住院患者相比，COVID-19 患者的死亡率更高。
